Clinical trial · Observational
The Effects of Radium-223 Dichloride Therapy on Radionuclide Bone Scan Lesions.
NCT03368989CI-TRIAL-00039015completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To describe the changes seen on bone scan and correlate them with changes in relative chemical biomarkers, patient's functional status and level of pain.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bony Metastases From Castrate Refractory Prostate Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radium-223 dichloride | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- treatment with radium-223 Dichloride (Xofigo)
- interventionNames
- Drug: Radium-223 dichloride
Primary outcomes (1)
- measure
- Change in number of osteoblastic bone lesions
- timeFrame
- Pretreatment (about 30 days before treatment) and post treatment (about 4 weeks after treatment)
- description
- number of lesions specified before and after the treatment with a bone scan
Secondary outcomes (9)
- measure
- functional status as indicated by score on the Eastern Cooperative Oncology Group (ECOG) performance scale
- timeFrame
- Pretreatment (about 1 to 3 days before each treatment) for a total of 6 treatments
- description
- The ECOG scale describes a patient's level of functioning in terms of their ability to care for themself, daily activity, and physical ability (walking, working, etc.). The possible scores on the scale are 0 to 5, with 0 being the best outcome and 5 being the worst outcome, details of each score are listed below. Grade 0 = Fully active, able to carry on all pre-disease performance without restriction Grade 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work Grade 2 = Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours Grade 3 = Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours Grade 4 = Completely disabled; cannot carry on any selfcare; totally confined to bed or chair Grade 5 = Dead
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Prostate cancer patients scheduled for treatment with Radium-223. Exclusion Criteria: * Patients not completing their treatment regimen for any reason
References
Publications (0)
Data not yet available
No reference posted for this study.